QPS Holdings, LLC divests its Neuropharmacology Business Unit
Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO. QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130940694/en/
QPS Neuropharmacology facility in Grambach, Austria. (Graphic: Business Wire)
Founded in 1999, QPS Neuropharmacology has built a strong global reputation for high quality services that are deeply scientifically rooted and has an undisputed track-record of serving a loyal and broad customer base globally. This long history of developing expertise within neuropharmacology preclinical studies has contributed to strong year-on-year growth and positioned the organization as a desirable acquisition target. QPS Neuropharmacology is based in a 2,700 m2 state-of-the-art facility in Grambach, Austria, and employs more than 80 employees. With on-site availability of validated transgenic and non-transgenic in-vitro and in-vivo models, QPS Neuropharmacology addresses multiple targets within the growing CNS area and represents a unique partner for biotech and pharma companies in their drug development process.
After the sale is complete, QPS will retain the European clinical division including the service capbilities in Austria, The Czech Republic, and Croatia where QPS has a long history of conducting late-phase clinical trials in neurodegenerative diseases, oncology and various rare diseases. This late-phase clinical capability will remain fully integrated with the QPS global clinical operational services organization, providing comprehensive global CRO services to pharmaceutical and biotech clients worldwide.
“The sale of QPS Neuropharmacology is a natural transition in the development of QPS as a full-service, global CRO focused on preclinical, bioanalysis and clinical research operational services. We believe that the neuropharmacology unit will be strengthened and continue to grow as part of the Scantox organization” saysBen Chien, President and CEO of QPS Holdings, LLC.
Manuela Prokesch, Director of QPS Neuropharmacology, continues: “This is a unique opportunity for us to bring our deep Neuropharmacology expertise to join a preclinical market leader, known for their high quality and customer-centric approach. We are looking forward to continuing to deliver our signature high-quality solutions to our clients while leveraging the synergies we can generate across the Scantox organization”.
QPS Neuropharmacology will continue to serve its valued clients as part of the Scantox organization. The combined company will have more than 300 employees across six sites offering lead optimization, neuropharmacology research services, regulatory toxicology and CMC/analytical services.
Advisors
Perella Weinberg Partners is serving as financial advisor to QPS Holdings, KPMG is serving as its tax advisor and Ropes & Gray together with Wolf Theiss are serving as its legal counsel. Lincoln International is serving as corporate finance advisor to Scantox, EY is serving as its financial and tax advisor, L.E.K. Consulting as its commercial advisor and Accura together with DORDA are serving as its legal counsel.
About QPS Holdings, LLC:
QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe, India and Asia. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
About Scantox:
Scantox is the leading Nordic pre-clinical GLP-accredited CRO, focused on pharmacology and regulatory toxicology, headquartered in Denmark with three subsidiaries in Sweden and one in Denmark. Based on decades of experience, the company is a trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, with a world known expertise within the Göttingen minipigs. The Company’s services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. Founded in 1977, Scantox is owned by Impilo, a leading Nordic healthcare investment company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231130940694/en/
Contact information
For further information:
Dr. Manuela Prokesch, Director of QPS Neuropharmacology, Manuela.Prokesch@qps.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo